Time to Raise the Bar to Psoriasis Area Severity Index 90 and 100
October 2015 | Volume 14 | Issue 10 | Editorials | 1086 | Copyright © October 2015
Iviensan F. Manalo BS,a Kathleen E. Gilbert BS,b and Jashin J. Wu MDc
aGeorgia Regents University Medical College of Georgia, Augusta, GA
bIndiana University School of Medicine, Indianapolis, IN
cDepartment of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA
- Carlin C, Feldman S, Krueger J, Menter A, Krueger G. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. Jun 2004;50(6):859-66.
- Langley R, Elewski B, Lebwohl M, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. Jul 2014;371(4):326-38.
- Papp K, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor
antibody for psoriasis. N Engl J Med. Mar 2012;366(13):1181-9.
- Gordon K, Leonardi C, Lebwohl M, et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. Dec 2014;71(6):1176-82.
- Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal
antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. Mar 2012;366(13):1190-9.
- Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis.
J Eur Acad Dermatol Venereol. Apr 2015;29(4):645-8.
- Griffiths C, Reich K, Gordon K. Revealing a clear path towards a new era in the management of psoriasis: Summary of presentations from the Novartis-Supported Satellite Symposium, held at the 23rd EADV Congress, Amsterdam,
the Netherlands, on 9th October 2014. EMJ Dermatol. 2014;2:42-8.
- Gottlieb A, Strober B, Lebwohl M, et al. Secukinumab in psoriasis: relationship
between clinical- and patient-reported outcomes using clinical trial data from the ERASURE and FIXTURE trials. Paper presented at: Presented at the 73rd annual American Academy of Dermatology conference, 2015; San Francisco, CA.
- Edson-Heredia E, Banerjee S, Zhu B, et al. A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses
from a phase 2 study in patients treated with ixekizumab. J Eur Acad Dermatol Venereol. Mar 2015:doi: 10.1111/jdv.13032. [Epub ahead of print].
- Viswanathan H, Chau D, Milmont C, et al. Total skin clearance results in improvements
in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatol Treat. Jul 2014;31:1-5.
- Revicki D, Willian M, Menter A, Saurat J, Harnam N, Kaul M. Relationship between
clinical response to therapy and health-related quality of life in patients with moderate to severe plaque psoriasis. Dermatology. 2008;216:260-70.
- Reich K, Griffiths C. The relationship between quality of life and skin clearance
in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. Arch Dermatol Res. Nov 2008;300(10):537-44.
- Takeshita J, Callis Duffin K, Shin D, et al. Patient-reported outcomes for psoriasis
patients with clear versus almost clear skin in the clinical setting. J Am Acad Dermatol. Oct 2014;71(4):633-41.
- Strober B, Langley R, Blicharski T, et al. AMAGINE-3: A Phase 3 Study of Efficacy
and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Patients. Paper presented at: 73rd Annual American Academy of Dermatology Conference, 2015; San Francisco,
- Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: 16-week results from the CLEAR study. Paper presented at: 73rd Annual American
Academy of Dermatology Conference, 2015; San Francisco, CA.
- Blauvelt A. Secukinumab Treatment Maintains Efficacy in Moderate to Severe
Plaque Psoriasis Through Second Year of Treatment: A Randomized Extension
of the ERASURE and FIXTURE Studies. Paper presented at: 73rd Annual
American Academy of Dermatology Conference, 2015; San Francisco, CA.
- Gordon K, Blauvelt A, Langley R, et al. Ixekizumab for Treatment of Moderate-to-Severe Plaque Psoriasis: 60-week Results from a Double-Blind Phase 3 Induction and Randomized Withdrawal Study (UNCOVER-1). Paper presented at: 73rd Annual American Academy of Dermatology Conference, 2015; San Francisco, CA.